Successful treatment of generalized pustular psoriasis with guselkumab
The purpose of the article: Generalized pustular psoriasis (GPP) is a rare auto-inflammatory disease. Patients with GPP may develop life-threatening complications, including sepsis, acute renal failure, neutrophilic cholangitis, high-output congestive heart failure, acute respiratory distress syndro...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/09546634.2024.2331807 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850115344129064960 |
|---|---|
| author | Martina Part |
| author_facet | Martina Part |
| author_sort | Martina Part |
| collection | DOAJ |
| description | The purpose of the article: Generalized pustular psoriasis (GPP) is a rare auto-inflammatory disease. Patients with GPP may develop life-threatening complications, including sepsis, acute renal failure, neutrophilic cholangitis, high-output congestive heart failure, acute respiratory distress syndrome and death. The therapy of GPP is very limited and the course of the disease is unpredictable.Materials and methods: We report a 60-year-old woman presenting with widespread and confluent erythematous-desquamative plaques with numerous small pustules covering almost 70% of the body surface area. Over the past years patient had undergone different types of conservative treatment regimens including topical therapy, acitretin, cyclosporin, methotrexate and long-term treatment with systemic corticosteroids. Considering the patient’s overall clinical condition, we proceed to initiate the biologic therapy with guselkumab.Results: Guselkumab (anti-IL-23) in the standard dose of 100 mg was administered subcutaneously at weeks 0, 4 and followed by a maintenance dose every 8 weeks. The remission of GPP was observed already after 12 weeks of treatment. The maintenance treatment in the period of 18 months shows stable clinical response.Conclusions: Our results support the evidence that guselkumab could provide an effective therapeutic approach in the treatment of GPP. |
| format | Article |
| id | doaj-art-7529b16af3ff469a8d1bca862ac19a81 |
| institution | OA Journals |
| issn | 0954-6634 1471-1753 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj-art-7529b16af3ff469a8d1bca862ac19a812025-08-20T02:36:35ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532024-12-0135110.1080/09546634.2024.2331807Successful treatment of generalized pustular psoriasis with guselkumabMartina Part0Department of Dermatovenerology, Faculty of Medicine, Comenius University in Bratislava and University Hospital in Bratislava, Bratislava, SlovakiaThe purpose of the article: Generalized pustular psoriasis (GPP) is a rare auto-inflammatory disease. Patients with GPP may develop life-threatening complications, including sepsis, acute renal failure, neutrophilic cholangitis, high-output congestive heart failure, acute respiratory distress syndrome and death. The therapy of GPP is very limited and the course of the disease is unpredictable.Materials and methods: We report a 60-year-old woman presenting with widespread and confluent erythematous-desquamative plaques with numerous small pustules covering almost 70% of the body surface area. Over the past years patient had undergone different types of conservative treatment regimens including topical therapy, acitretin, cyclosporin, methotrexate and long-term treatment with systemic corticosteroids. Considering the patient’s overall clinical condition, we proceed to initiate the biologic therapy with guselkumab.Results: Guselkumab (anti-IL-23) in the standard dose of 100 mg was administered subcutaneously at weeks 0, 4 and followed by a maintenance dose every 8 weeks. The remission of GPP was observed already after 12 weeks of treatment. The maintenance treatment in the period of 18 months shows stable clinical response.Conclusions: Our results support the evidence that guselkumab could provide an effective therapeutic approach in the treatment of GPP.https://www.tandfonline.com/doi/10.1080/09546634.2024.2331807Generalized pustular psoriasistherapy of GPPguselkumabinhibitor of IL-23 |
| spellingShingle | Martina Part Successful treatment of generalized pustular psoriasis with guselkumab Journal of Dermatological Treatment Generalized pustular psoriasis therapy of GPP guselkumab inhibitor of IL-23 |
| title | Successful treatment of generalized pustular psoriasis with guselkumab |
| title_full | Successful treatment of generalized pustular psoriasis with guselkumab |
| title_fullStr | Successful treatment of generalized pustular psoriasis with guselkumab |
| title_full_unstemmed | Successful treatment of generalized pustular psoriasis with guselkumab |
| title_short | Successful treatment of generalized pustular psoriasis with guselkumab |
| title_sort | successful treatment of generalized pustular psoriasis with guselkumab |
| topic | Generalized pustular psoriasis therapy of GPP guselkumab inhibitor of IL-23 |
| url | https://www.tandfonline.com/doi/10.1080/09546634.2024.2331807 |
| work_keys_str_mv | AT martinapart successfultreatmentofgeneralizedpustularpsoriasiswithguselkumab |